Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has provided an announcement.
EBR Systems, Inc. has successfully completed the first commercial implants of its WiSE CRT System in the US, following recent FDA approval. This milestone highlights the clinical importance of leadless left ventricular pacing, particularly for patients who were previously untreatable or at high risk. The company is on track to initiate a limited market release and expects reimbursement payments to begin in October 2025. This advancement positions EBR Systems to strengthen its market presence and potentially improve outcomes for heart failure patients.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Silicon Valley-based EBR Systems, Inc. is a company focused on improving cardiac rhythm disease treatment through its innovative wireless cardiac pacing technology. The company’s proprietary WiSE technology eliminates the need for traditional pacing leads, addressing complications and reliability issues in cardiac rhythm management. Their initial product targets heart failure patients requiring Cardiac Resynchronization Therapy (CRT), with future plans to expand into other areas such as bradycardia.
Average Trading Volume: 1,116,727
Learn more about EBR stock on TipRanks’ Stock Analysis page.